Caren van Roekel

170 Chapter 6 TABLE 1. Baseline characteristics (n=36 patients). Characteristic N or median (range) All patients Responders Non-responders Gender Male 17 6 11 Female 19 6 13 Age (y) at therapy 64 (40-84) 67.5 (44-84) 63 (40-74) Primary tumor type Colorectal carcinoma 21 8 13 Breast carcinoma 4 1 3 Cholangiocarcinoma 4 0 4 Uveal melanoma 4 1 3 Neuro-endocrine neoplasm 1 1 0 Pancreas carcinoma 1 0 1 Thymoma 1 1 0 Liver volume (mL) 1,938 (1,155 – 3,842) Metabolic tumor volume (mL) 171 (5 -1,993) Administered activity (MBq) 6705 (3676 – 12,897) 7632 (3763 – 10,217) 6705 (3676 – 12,897) Previous treatment Locoregional (liver) 8 3 5 Systemic 34 11 23 None 2 1 1 WHO status 0 29 9 20 1 5 2 3 Unknown 2 1 1 Extrahepatic disease at baseline No 26 8 18 Yes 10 4 6 Three patients from the HEPAR I study were administered an activity corresponding to a uniform absorbed dose of 80 Gy to the target volume, all other patients were administered an activity that corresponded to 60 Gy. Median administered activity was 6705 MBq, with a range of 3676-12897 MBq. Thirty-five patients received whole liver treatment and one patient received lobar treatment.